Dec 9, 2024 · Adstiladrin (nadofaragene firadenovec-vncg) is a gene therapy used to treat high-risk Bacillus CalmetteGuérin (BCG)-unresponsive non-muscle invasive bladder cancer. Includes …

ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive …

ADSTILADRIN® is indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-Muscle Invasive Bladder Cancer (NMIBC) with carcinoma in situ (CIS ...

Clinical overview Indication: ADSTILADRIN® (nadofaragene firadenovec-vncg) is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk …

May 6, 2024 · ADSTILADRIN ® (nadofaragene firadenovec-vncg) is the first and only FDA-approved intravesical non-replicating gene-therapy for the treatment of adult patients with high-risk Bacillus …

Adstiladrin is also called nadofaragene firadenovec-vncg. Adstiladrin is a gene therapy that uses a non-replicating adenoviral vector (a modified virus that cannot multiply) to deliver a gene to bladder cells. …

Nov 26, 2025 · It just uses the bladder cancer cells as a temporary factory to produce interferon where it's locally needed to treat those and target those cancer cells. So, nadofaragene firadenovec, which …

Apr 1, 2025 · Abstract On December 16, 2022, the FDA approved the adenoviral vector-based gene therapy nadofaragene firadenovec-vncg (brand name Adstiladrin) for the treatment of adult patients …

Nadofaragene firadenovec uses a recombinant adenovirus that encodes for interferon alpha-2b gene. Intravesical instillation of interferon alone for bladder cancer produced complete responses that were …

Jul 22, 2024 · As you likely know, Adstiladrin (nadofaragene firadenovec-vncg) was recently approved for bladder cancer. It is a gene therapy currently used for adult patients with high-risk Bacillus …